Search

Your search keyword '"Manyam, Ganiraju C"' showing total 4 results
Start Over Author "Manyam, Ganiraju C" Publisher american society of hematology
4 results on '"Manyam, Ganiraju C"'

1. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma

Author

Xu-Monette, Zijun Y., primary, Li, Ling, additional, Byrd, John C., additional, Jabbar, Kausar J., additional, Manyam, Ganiraju C., additional, Maria de Winde, Charlotte, additional, van den Brand, Michiel, additional, Tzankov, Alexandar, additional, Visco, Carlo, additional, Wang, Jing, additional, Dybkaer, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W. L., additional, Huh, Jooryung, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J. M., additional, Møller, Michael B., additional, Parsons, Ben M., additional, Winter, Jane N., additional, Wang, Michael, additional, Hagemeister, Frederick B., additional, Piris, Miguel A., additional, Han van Krieken, J., additional, Medeiros, L. Jeffrey, additional, Li, Yong, additional, van Spriel, Annemiek B., additional, and Young, Ken H., additional

Published
2016
Full Text
View/download PDF

2. MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

Author

Xu-Monette, Zijun Y., primary, Møller, Michael B., additional, Tzankov, Alexander, additional, Montes-Moreno, Santiago, additional, Hu, Wenwei, additional, Manyam, Ganiraju C., additional, Kristensen, Louise, additional, Fan, Lei, additional, Visco, Carlo, additional, Dybkær, Karen, additional, Chiu, April, additional, Tam, Wayne, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W. L., additional, van Krieken, J. Han, additional, Huang, Qin, additional, Huh, Jooryung, additional, Ai, Weiyun, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J. M., additional, Wu, Lin, additional, Zhao, Xiaoying, additional, Bueso-Ramos, Carlos E., additional, Wang, Sa A., additional, Go, Ronald S., additional, Li, Yong, additional, Winter, Jane N., additional, Piris, Miguel A., additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2013
Full Text
View/download PDF

3. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Author

Hu, Shimin, primary, Xu-Monette, Zijun Y., additional, Balasubramanyam, Aarthi, additional, Manyam, Ganiraju C., additional, Visco, Carlo, additional, Tzankov, Alexander, additional, Liu, Wei-min, additional, Miranda, Roberto N., additional, Zhang, Li, additional, Montes-Moreno, Santiago, additional, Dybkær, Karen, additional, Chiu, April, additional, Orazi, Attilio, additional, Zu, Youli, additional, Bhagat, Govind, additional, Richards, Kristy L., additional, Hsi, Eric D., additional, Choi, William W. L., additional, Han van Krieken, J., additional, Huang, Qin, additional, Huh, Jooryung, additional, Ai, Weiyun, additional, Ponzoni, Maurilio, additional, Ferreri, Andrés J. M., additional, Zhao, Xiaoying, additional, Winter, Jane N., additional, Zhang, Mingzhi, additional, Li, Ling, additional, Møller, Michael B., additional, Piris, Miguel A., additional, Li, Yong, additional, Go, Ronald S., additional, Wu, Lin, additional, Medeiros, L. Jeffrey, additional, and Young, Ken H., additional

Published
2013
Full Text
View/download PDF

4. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Author

Shimin Hu, Xu-Monette, Zijun Y., Balasubramanyam, Aarthi, Manyam, Ganiraju C., Visco, Carlo, Tzankov, Alexander, Wei-min Liu, Miranda, Roberto N., Li Zhang, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Youli Zu, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W. L., van Krieken, J. Han, and Qin Huang

Subjects
*CD30 antigen, *B cells, *LYMPHOMAS, *GENE expression, *RITUXIMAB, *B cell receptors, *GENETICS, *DISEASES
Abstract

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in ~14% of DLBCL patients. Patients with CD30+ DLBCL had superior 5-year overall survival (CD30+, 79% vs CD30-, 59%; P = .001) and progression-free - survival (P = .003). The favorable outcome of CD30 expression was maintained in born the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the upregulation of genes encoding negative regulators of nuclear factor κB activation and lymphocyte survival, and downregulation of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD30+ DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trials, it seems appropriate to consider CD30+ DLBCL as a distinct subgroup of DLBCL. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results